查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190466

化妝品Peptide合成市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Cosmetic Peptide Synthesis Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，化妝品Peptide合成市場預計將以 5.5% 的複合年增長率註冊。

大流行對化妝品行業，包括化妝品Peptide合成行業產生了整體的負面影響。 例如，2021 年 10 月發表的一項研究報告《疫情期間的美麗。在使用方面，眼部、唇部和皮膚化妝品的使用量有望恢復到 COVID 之前的水平。 儘管預計 2020 年會出現大幅下降，但美國化妝品行業預計使用量將恢復到 COVID 前的結果，並帶有 COVID 後的意向。 預計護膚品類別在 COVID 中期幾乎不會下降，而在 COVID 後會有所增長。 強烈建議將護膚產品作為新產品系列推出，因為它們在改變行業的大流行病中是可持續的。 同樣，在 2020 年 10 月發表在國際飲食失調雜誌上的另一篇論文“了解 COVID-19 期間美容行業停工的影響”中，斯威本心理健康中心 (CMH) 的研究人員領導的一項研究發現，大多數人們報告說，自 COVID-19 開始以來，他們花在外表上的時間減少了，但那些高度畸形的人繼續對自己的外表感到難為情。說

眼睛和皮膚疾病的增加是市場增長的重要因素之一。 根據加拿大青光眼研究協會的數據，到 2021 年，加拿大將有大約 400,000 人患有青光眼。 根據同一份文件，隨著人口老齡化和嬰兒潮一代的老齡化，未來患有青光眼的人數將會增加。 這將增加對美容□的需求。 因此，增加未來的市場增長。 同樣，根據澳大利亞健康與福利研究所的數據，2021 年約有 166,878 例皮膚黑色素瘤新病例被確診。 Soukur 說有 9,869 名男性和 7,009 名女性被確診。 2019 年，年齡標準化死亡率為每 10 萬人 4.5 人（男性 6.6 人，女性 2.8 人）。 2021 年的年齡標準化死亡率估計為每 100,000 人 4.0 人（男性 5.6 人，女性 2.6 人）。 皮膚黑色素瘤的死亡率預計會隨著年齡的增長而增加。 因此，可以通過使用美容□來避免皮膚癌的增加。 因此，預計癌症患病率的增加將增加未來的市場增長。

採用化妝品□的主要挑戰之一是人們仍然認為化妝品不具有藥用價值。 例如，2021 年 12 月在國家醫學圖書館發表的一篇論文是權威的，證明患有糖尿病性視網膜病變的人與進行連續眼科篩查之間存在直接關聯。他說沒有研究。 早期檢測是能夠為患有後節段疾病的患者提供治療的因素之一，但是，由於患者開始治療緩慢，缺乏意識阻礙了市場增長。 然而，低意識可能會延遲患者開始治療，阻礙市場增長。

化妝品Peptide合成市場趨勢

眼部護理領域預計在預測期內將佔據很大的市場份額

眼睛疲勞加劇是市場增長的主要驅動力之一。 例如，根據世界衛生組織 2021 年 10 月的報告，全球約有 22 億人患有近視或遠視，其中約有 10 億的視力損害病例是可以預防或預防的。全球視力損害病例的高負擔和治療潛力是治療眼部相關疾病的藥物需求非常高的原因，這推動了研究市場的增長。

青光眼流行病學”，根據 2020 年 11 月發表的一項研究報告。 根據過去、現在和未來的預測，青光眼是由血管、遺傳、解剖學和免疫學因素共同引起的，可導致不可逆轉的失明，使其成為僅次於白內障的第二大失明原因。據說是一個嚴重的健康問題，因為它是第二高的 根據同一項研究，全球估計有 5750 萬人患有原發性開角型青光眼 (POAG)，預計到 2040 年這一數字將達到 1.118 億，這是一個非常高的數字。由於患者數量大幅增加，全球對有效療法的需求也有望增加。 對治療劑不斷增長的需求將增加美容□的消費，促進未來的市場增長。

此外，老化是視力損害的一個新因素。 根據聯合國公佈的《2020年世界人口老齡化亮點》，2020年世界老年人口（65歲及以上）將達到7.27億，預計到2050年底將達到15億。 全球老年人口的增加將對研究領域的增長產生重大影響，因為一些眼病與年齡有關，並且已證實其患病率在老齡化社會中最高。我猜。 隨著年齡的增長，我們需要攝入更多的美容□。 因此，由於上述因素，未來市場可能會增長。

北美有望在預測期內主導市場

預計在整個預測期內，北美將主導整個化妝品□合成市場。 這一優勢歸因於眼部和皮膚病患病率的增加、公共和私人組織的研發和投資增加以及意識計劃。

美國製藥業長期以來一直是新藥發現的領導者，美國研究與製藥商協會 (PhRMA) 的成員繼續走在前列。 根據美國研究和製藥製造商協會 2020 年版的數據，美國製藥公司在 2019 年的研發支出約為 830 億美元，高於 2010 年的 507 億美元。 根據美國疾病控制與預防中心（CDC）公佈的數據，2020年約有410萬美國人患有糖尿病視網膜病變，近90萬美國人面臨視力受損的視網膜病變威脅。據說 糖尿病性視網膜病變是具有代表性的眼科疾病之一。 患病率的上升將增加大量人口的治療需求，並推動該國的市場增長。

該國皮膚病的增加是市場增長的關鍵因素。 例如，加拿大皮膚病協會2020年發布的一份報告稱，約有8000人患有黑色素瘤皮膚癌，其中男性約4400人，女性約3600人。 黑色素瘤目前是加拿大第七大最常見的癌症，也是少數在加拿大人中患病率上升的癌症之一。 根據 2019 年 10 月發表的“膠原蛋白補充劑改善皮膚水合作用、彈性、粗糙度和密度”研究，“膠原蛋白補充劑改善皮膚水合作用、彈性、粗糙度和密度：隨機安慰劑的結果——根據對照、盲法研究、安慰劑對照臨床試驗已經證實，老化的皮膚可以用可以恢復皮膚水分含量、彈性和密度的營養素來對抗。 因此，研究表明，使用□可以減緩通常伴隨衰老而來的膠原蛋白生成的下降。

對皮膚病學的認識也是推動市場增長的因素之一。 例如，2022 年 5 月將舉辦兒科皮膚病學管理挑戰國際會議 (ICCDMP)（加拿大蒙特利爾）和法醫病理學和皮膚病學國際會議 (ICFPD)（加拿大溫哥華）。 同樣，許多會議在 6 月、7 月、8 月和 9 月舉行，預計 2023 年將舉行更多會議。 在這些會議上，討論了與皮膚病相關的問題和治療。 由於美容□在皮膚治療中發揮著重要作用，會議數量的增加有望提高人們對皮膚疾病的認識，並增加針對此類疾病的美容□相關產品的消費量。 因此，市場規模將會擴大。

因此，上述因素預計將在預測期內推動該地區的市場增長，並有助於其在全球化妝品□合成市場中佔據顯著的市場份額。

化妝品Peptide合成市場競爭分析

化妝品Peptide合成市場與幾家主要參與者競爭適中。 一些公司通過收購、合併和研究合作等各種戰略擴大其市場地位，而另一些公司則推出新產品以保持其市場份額。 2019年5月，CEM公司推出全球首台大型全自動微波Peptide合成儀“Liberty PRO”。 該系統能夠利用最大 15 升的反應容器每批次合成 1 千克粗□，具有無與倫比的純度、速度和廢物減少，推動市場收入份額。 目前在收入方面主導該行業的主要參與者是 AAPPTec、CSBio Company Inc.、Biotage AB、Bachem Holding AG 和部分 CEM Corporation。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 眼睛和皮膚病的增加
    • 激活研發
  • 市場製約因素
    • 化妝品Peptide審批的嚴格規定
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按技術
    • 固相
    • 液相
    • 雜交和重組
  • 通過使用
    • 抗衰老
    • 眼部護理
    • 抗色素沉著
    • 頭髮生長
  • 最終用戶
    • 製藥和生物技術公司
    • 合同開發和製造組織 (CDMO)
    • 學術和研究機構
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • AAPPTec
    • Activotec
    • Active Peptide
    • Bachem Holding AG
    • Bio Basic Inc
    • Bio Synthesis
    • CEM Corporation
    • Creative Peptides
    • CSBio Company Inc.
    • GenScript
    • Merck KGaA
    • RS Synthesis, LLC
    • vivitide

第7章 市場機會與今後動向

簡介目錄
Product Code: 90442

The cosmetic peptide synthesis market is expected to register a CAGR of 5.5 % over the forecast period of 2022-2027.

The pandemic has an overall negative impact on the cosmetic industry including the cosmetic peptide synthesis industry. For instance, the research study published in October 2021, titled "Beauty During a Pandemic: The Impact of COVID-19 on the Cosmetic Industry" stated significant differences in cosmetic usage; however, post-COVID predicted usage indicates that cosmetic usage will revert back to pre-COVID levels for eye, lip, and skin cosmetics. Despite that the US Cosmetic Industry expected a significant decline in 2020, usage is predicted to return to pre-COVID results for post intentions. The skincare category had little decline mid-COVID and is expected to increase post-COVID. Implementing skincare products as a new product line is highly recommended due to its sustainability through an industry-changing pandemic. Similarly, another article published in October 2020 in the International Journal of Eating Disorders titled "Understanding impacts of the beauty industry shutdown during COVID-19" stated that the study led by researchers from Swinburne's Centre for Mental Health (CMH) has found that while most people reported spending less time investing in their appearance since COVID-19 began, individuals with high dysmorphic concern continued to feel self-conscious about their appearance.

Factors such as increasing disorders of eyes and skin are one of the key factors for the growth of the market. According to Glaucoma Research Society of Canada around 400,000 people were suffering from Glaucoma in Canada for the year 2021. According to the same source with increasingly ageing population and an aging baby boom generation, many more people will have glaucoma in the future. This would increase the demand for the cosmpetic peptides. Thus, increasing the growth of the market in the upcoming future. Similarly, according to the Australian Institute of Health and Welfare in 2021, around 16,6878 new cases of melanoma of the skin were diagnosed. The same soucre stated that 9,869 males and 7,009 females were diagnosed. In 2019, the age-standardised mortality rate was 4.5 deaths per 100,000 persons (6.6 for males and 2.8 for females). In 2021, it is estimated that the age-standardised mortality rate will be 4.0 deaths per 100,000 persons (5.6 for males and 2.6 for females). The mortality rate for melanoma of the skin is expected to increase with age. Hence, increasing skin cancer could be avioded by the usage of cosmetic peptides. Thus, increasing prevalence of cancer would increase the market growth in upcoming future.

Awareness is one of the key issue for adopting the cosmetic peptides are people still believes that cosmtics does not provide medicinal benifits. For instance, in December 2021 a paper published in National Library of Medicine stated that there is no conclusive study that proves direct correlation between people suffering from diabetic retinopathy and going for continuous eye screening. Early detection is one of the factors that could provide the treatment for the patients suffering from posterior segment eye disorders however lack of awareness would hinder the growth of the market as patient would start treatment at the later stages. Hence, due to above mentioned factors the market is likely to grow in the future.

Cosmetic Peptide Synthesis Market Trends

Eye Care Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Increasing eye burden is one of the key factors for the growth of the market. For instance, according to the October 2021 report of the World Health Organization, about 2.2 billion people around the world have near or distance vision impairment, of which approximately 1 billion cases of vision impairment can be prevented or could have been prevented which shows the high burden of the cases of vision impairment around the world and possibility of treatment which is why there is a very high demand of the therapeutics for the diseases associated with eyes that are driving the growth of the studied market.

According to the research study published in November 2020, titled "Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future", glaucoma occurs due to the combination of vascular, genetic, anatomical, and immune factors and is a significant health concern as it can cause irreversible blindness and is the second leading cause of blindness after cataracts. As per the same study, it is estimated that approximately 57.5 million people around the world are affected by the primary open-angle glaucoma (POAG) which is expected to reach 111.8 million by 2040, which is a very significant increase and thus, the demand for effective therapeutics is also expected to increase around the world. Increasing therapuetics demands would increase the consumption of cosmetic peptides which will increase the market growth in the future.

Ageing is also an additional factor for eye sight related disorder. According to the World Population Ageing Highlight of 2020 published by the United Nations, the global geriatric population (people of age 65 years or more) was 727 million in 2020 and is expected to reach 1.5 billion by the end of the 2050. Thus, growing global geriatric population will have a significant impact on the growth of the studied segment as it is observed that some of the eye disorders are age related and their prevalence was found highest in the ageing population. Increasing ageing populaiton would require to consume higher amount of cosmetic peptides. Hence, due to above mentioned factors the market is likely to grow in the future.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall cosmetic peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of eye and skin disorders, and increasing R&D and investment via public and private organizations coupled with awareness programs.

The pharmaceutical sector in United States has long been a leader in the creation of new medications, and member businesses of the Pharmaceutical Research and Manufacturers of America (PhRMA) continue to remain at the forefront. According to the Pharmaceutical Research and Manufacturers of America 2020, pharmaceutical companies in United States spent roughly USD 83 billion on R&D in 2019, up from USD 50.7 billion in 2010. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2020 around 4.1 million Americans are affected with diabetic retinopathy, and nearly 900,000 Americans are threatened with vision-damaging retinopathy. Diabetic retinopathy is one of the leading disorders of eye disorders. Increasing prevalence will increase the demand for treatment in huge population which will boost the growth of the market in the country.

Increasing number of skin disorders in the country is a key factor for the growth of the market. For instance, in 2020 a report published by Canadian Dermatology Association stated that around 8,000 people are suffering from Melanoma skin cancer our of which around 4,400 were men and 3,600 were women. Melanoma is now the 7th most common cancer in Canada and one of the few cancers with incidence rates on the rise among Canadians. According to the research study published in October 2019, titled "A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study" stated that placebo-controlled clinical trial confirmed that skin aging could be addressed using nutrients that are able to restore skin hydration, elasticity, and density. Hence, the research suggests that the use of peptides can slow down the decline in collagen production that usually occurs with ageing.

Awareness of dermatology is another factor in the growth of the market. For instance, in May 2022 there are two conferences namely, the "International Conference on Challenges in Dermatology Management in Pediatrics (ICCDMP)" (Montreal, Canada) and the "International Conference on Forensic Pathology and Dermatology (ICFPD)" (Vancouver, Canada) are expected to held. Similarly, there are many conferences in June, July, August, and September followed by conferences in 2023 are expected to held. These conferences would discuss the issues and treatment reated to dermatological disorders. As cosmetics peptides play a crucial role in the treatment of skins, as the numebr of conferences increases the awarenss for skin disoder will increase along with the consumption of the cosmetic peptide related products for those disorders. Hence, this will increase the market growth.

Hence, the above mentioned factors are likely to fuel the market growth in this region across the forecast period, contributing to its outstanding market share in the global cosmetic peptide synthesis market​

Cosmetic Peptide Synthesis Market Competitive Analysis

The cosmetic peptide synthesis market is moderately competitive, with several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions, mergers, and research collaborations, while others are introducing new products to maintain their market share. In May 2019, CEM Corporation launched Liberty PRO, the world's first-ever large-scale automated microwave peptide synthesizer. The system can synthesize 1 kg of crude peptide per batch utilizing a reaction vessel, with sizes up to 15 liters with unmatched purity, speed, and waste reduction fueling the market revenue share. A few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc., Biotage AB, Bachem Holding AG, and CEM Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Eye and Skin Disorders
    • 4.2.2 Increasing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulation for Approval of Cosmetic Peptide
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Solid-Phase
    • 5.1.2 Liquid-Phase
    • 5.1.3 Hybrid and Recombinant
  • 5.2 By Application
    • 5.2.1 Anti Ageing
    • 5.2.2 Eye Care
    • 5.2.3 Anti Pigmentation
    • 5.2.4 Hair Growth
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Development and Manufacturing Organization (CDMO)
    • 5.3.3 Academic and Research Institutes
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AAPPTec
    • 6.1.2 Activotec
    • 6.1.3 Active Peptide
    • 6.1.4 Bachem Holding AG
    • 6.1.5 Bio Basic Inc
    • 6.1.6 Bio Synthesis
    • 6.1.7 CEM Corporation
    • 6.1.8 Creative Peptides
    • 6.1.9 CSBio Company Inc.
    • 6.1.10 GenScript
    • 6.1.11 Merck KGaA
    • 6.1.12 RS Synthesis, LLC
    • 6.1.13 vivitide

7 MARKET OPPORTUNITIES AND FUTURE TRENDS